Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer

Immunomodulation checkpoints usually adopted by healthy cells by tumors might cause an imbalance between host surveillance and tumor progression. Several tumors are incredibly resistant to standard treatment. The dynamic and long-lasting tumor regressions caused by antibodies targeting the PD-1/PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkholifi, Faisal K., Alsaffar, Rana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694305/
https://www.ncbi.nlm.nih.gov/pubmed/36363529
http://dx.doi.org/10.3390/medicina58111572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694305/
https://www.ncbi.nlm.nih.gov/pubmed/36363529
http://dx.doi.org/10.3390/medicina58111572

Ejemplares similares